Abstract:
The invention provides a non-tactile control arrangement including an array of light sensors 5, an array of light emitters 4, each one of which is adapted to illuminate, and thereby cause an output signal to be generated by, at least a respective one of the array of light sensors, detection means for detecting the output of each of one of array of light sensors and providing an output signal indicative of a change of state of the outputs of the array of sensors. The presence or absence of illumination of any one or more of the light sensors is detected by the detection means which provide an output in the form of a set of binary digits, in a suitable format, for use in the control of equipment, for example, a computer. The arrangement may be incorporated in a frame 1.
Abstract:
A medical system, including a medical device having a plurality of deployable arms, and at least one electrode on at least one of the plurality of arms; and an electric signal generator in communication with the medical device, the electric signal generator programmed to deliver pulsed energy to the medical device sufficient to induce irreversible electroporation ablation.
Abstract:
A medical device including a catheter having a shaft with a distal portion; a first plurality of substantially hemispherical electrodes coupled to the distal portion; a second plurality of substantially hemispherical electrodes coupled to the shaft proximal of the first plurality, where the second plurality of electrodes are oriented substantially orthogonal to the first plurality of electrodes; and an additional electrode coupled to the shaft. A console may have a processor in electrical communication with the first and second plurality of electrodes and the reference electrode, the processor programmed to obtaining a monophasic action potential recording from at least one of the first and second plurality of electrodes.
Abstract:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as "PVA compounds"), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
Abstract translation:本发明一般涉及治疗化合物领域,更具体地涉及式(X)的某些丙酮酰胺化合物(为了方便起见,统称为“PVA化合物”),其特别是抑制尘螨组 1肽酶变应原(例如,Der p 1,Der f 1,Eur m 1)。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体外和体内的用途,以抑制尘螨组1肽酶变应原和治疗由 尘螨组1肽酶变应原; 通过抑制尘螨组1肽酶变应原而得到改善; 哮喘; 鼻炎; 过敏性结膜炎 特应性皮炎; 由尘螨触发的过敏状况; 由尘螨组1肽酶变应原触发的过敏状况; 和犬特应性
Abstract:
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aldehyde compounds of the following formula (A) (for convenience, collectively referred to herein as "ALD compounds"), which, inter alia , inhibit a dust mite Group 1 peptidase allergen ( e.g. , Der p 1, Der f 1, Eur m 1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo , to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
Abstract translation:本发明一般涉及治疗化合物领域,更具体地涉及以下式(A)的某些醛化合物(为了方便起见,统称为“ALD化合物”),其特别地抑制尘螨 第1组肽酶变应原(例如,Der p 1,Der f 1,Eur m 1)。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体外和体内的用途,以抑制尘螨组1肽酶变应原和治疗由 尘螨1组肽酶变应原; 通过抑制尘螨组1肽酶变应原而得到改善; 哮喘; 鼻炎; 过敏性结膜炎 特应性皮炎; 由尘螨触发的过敏状况; 由尘螨组1肽酶变应原触发的过敏状况; 和犬特应性
Abstract:
The invention provides an apparatus (10) for mounting at least one electronic financial transaction (EFT) data input device (34) to a surface. The apparatus (10) comprises a mounting platform (12) which is fixedly attachable to said surface; and at least one adaptor (14) which, in use, receives and secures a first EFT data input device (34) thereto, wherein said at least one adaptor (14) is detachably mountable to said mounting platform (12).